European Society for Medical Oncology (ESMO) Congress 2021

6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer

Kanas Chan, 20211123000000

Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.

MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC

20211115130000

Adding ribociclib (KISQALI, Novartis) to letrozole yields significant and consistent overall survival (OS) benefit compared with letrozole alone in the first-line setting for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), according to the final OS analysis of the MONALEESA-2 trial presented at ESMO 2021.

CheckMate 743: 3-year OS data confirm NIVO + IPI as standard of care for mesothelioma

NIVO + IPI survival benefit persists over 3 years in mesothelioma: CheckMate 743

Pearl Toh, 20211103140100

The combination immunotherapy of nivolumab (NIVO) and ipilimumab (IPI) continues to provide durable survival benefit over chemotherapy in the first-line setting in patients with unresectable malignant pleural mesothelioma (MPM), despite the patients having been off immunotherapy for 1 year, according to the 3-year data from the CheckMate 743 trial presented at ESMO 2021.

Pembrolizumab extends RFS in stage II melanoma

Roshini Claire Anthony, 20211101160001

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease

Natalia Reoutova, 20211014000000

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]

ADT-docetaxel-abiraterone: A winning combo for mCSPC

Roshini Claire Anthony, 20211007180001

Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.

Pembro + chemo: ‘Practice-changing’ in advanced cervical cancer

Pearl Toh, 20210929141000

Adding pembrolizumab to chemotherapy with or without bevacizumab significantly extends overall survival (OS) by 8 months in women with recurrent, persistent or metastatic cervical cancer, according to the KEYNOTE-826 study presented at ESMO 2021.

Palbociclib plus letrozole prolongs survival in Asian patients with advanced breast cancer

Dr Margaret Shi, 20210929034409

Palbociclib plus letrozole as first-line treatment improves progression-free survival (PFS) vs placebo plus letrozole in postmenopausal Asian patients with advanced oestrogen receptor (ER)–positive and HER2-negative breast cancer (BC), primary results of the phase III PALOMA-4 study have shown.

Olanzapine a favourable alternative to dexamethasone for CINV

Audrey Abella, 20210927100000

Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.

Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer

Dr Margaret Shi, 20210927071610

A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.